BPC-157: The Most Researched Healing Peptide in the World
Over 100 peer-reviewed studies. Three published human trials. Zero serious adverse events. Here's what 30+ years of research tells us about the peptide that accelerates healing across every tissue type it's been tested on.
Studies Published
in Human Pilot
From Gastric Juice
Established (LD1)
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protective protein naturally found in human gastric juice. It has been studied more extensively than virtually any other research peptide — with over 100 published papers spanning gut healing, tendon repair, nerve regeneration, cardiovascular protection, and multi-organ cytoprotection.
What makes BPC-157 remarkable isn't just that it works in any single study — it's the consistency of positive results across every tissue type it's been tested on, combined with a safety profile so clean that researchers have never been able to establish a lethal dose even at extreme concentrations. The compound appears to work by orchestrating the body's own healing systems rather than overriding them — upregulating growth factors, optimizing nitric oxide signaling, and promoting new blood vessel formation exactly where injured tissue needs it most.
Three human studies have now been published (as of early 2026), all showing positive results with zero adverse events. Millions of people worldwide have used BPC-157 based on its preclinical promise, and the overwhelming weight of both scientific and real-world evidence points in one direction: this peptide accelerates healing.
This is the most common question about BPC-157, and the answer is straightforward: FDA approval costs $1-2 billion and takes 10-15 years, and no pharmaceutical company will invest that in a naturally-derived peptide sequence they can't patent exclusively. BPC-157's amino acid sequence comes from human gastric juice — it can't be owned. This creates a funding paradox where the very thing that makes BPC-157 appealing (it's a fragment of something your body already produces) is what prevents it from going through the traditional approval pipeline. The 100+ published studies, three human trials, and decades of clinical use in some countries exist despite this economic barrier, not because anyone solved it.
Compound Profile
Body Protection Compound-157
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids) | Molecular weight: ~1,419 Da | Origin: Partial fragment of human gastric juice protein BPC | Primary research: University of Zagreb (Prof. Predrag Sikiric), 100+ published papers since early 1990s | Unique property: Stable in gastric acid — effective both orally and by injection | Routes: Subcutaneous injection (most common), oral (especially for GI targets), intramuscular, intra-articular, intravesical | Standard dose: 250-500 mcg 1-2x daily (SC); higher doses studied in human trials (up to 20 mg IV) | Safety: No lethal dose established (LD1 not achieved); negative limit test at 2 g/kg IV and IG in mice; no organ toxicity, no mutagenicity in any study
How BPC-157 Works: Five Healing Pathways
BPC-157 doesn't work through a single mechanism — it orchestrates healing across multiple pathways simultaneously. This is both what makes it so effective across diverse tissue types and what makes it difficult to reduce to a simple drug-target explanation. Think of it less like a conventional drug that hits one receptor and more like a master coordinator of the body's healing response.
Angiogenesis: Building New Blood Vessels
BPC-157's most thoroughly documented mechanism is its ability to promote angiogenesis — the formation of new blood vessels. It upregulates VEGF (vascular endothelial growth factor) and activates the VEGFR2 signaling pathway, creating new capillary networks that deliver oxygen and nutrients to injured tissue. This is why BPC-157 is particularly effective for poorly-vascularized tissues like tendons and ligaments, where limited blood supply is the primary bottleneck for healing.
NO System: The Intelligent Modulator
Unlike simple NO boosters or blockers, BPC-157 acts as a nitric oxide modulator — it counters both NO excess and NO deficiency depending on what the tissue needs. This sophisticated bidirectional regulation via the Akt-eNOS axis is why the peptide can protect against conditions caused by too much NO (like certain types of inflammation) AND conditions caused by too little NO (like impaired blood flow). It doesn't push in one direction; it restores balance.
Growth Factor Cascade
BPC-157 upregulates multiple growth factors beyond VEGF: EGF (epidermal growth factor) for mucosal healing, HGF (hepatocyte growth factor) for liver and tissue repair, FGF (fibroblast growth factor) for connective tissue, and — notably — growth hormone receptor expression. This broad growth factor engagement, confirmed in the 2025 AJSM systematic review, likely explains why the peptide shows healing benefits across such diverse tissue types rather than being limited to one application.
Cell Migration & Tissue Remodeling
Through activation of the FAK-paxillin pathway, BPC-157 enhances cell migration, adhesion, and tissue remodeling — the fundamental cellular processes that drive wound healing. Studies show it promotes tendon outgrowth, stimulates tendocyte growth, increases fibroblast proliferation, and improves collagen fiber organization. Damaged tissue doesn't just heal — it remodels more effectively toward functional restoration.
What emerges from this multi-pathway picture is a compound that doesn't simply accelerate one healing process — it coordinates the entire healing response. New blood vessels deliver resources (angiogenesis). NO signaling optimizes the local environment (modulation). Growth factors activate the right cell populations (cascade). Cells migrate and rebuild (remodeling). And the nervous and immune systems are protected from collateral damage throughout (neuroprotection). This coordinated action is likely why BPC-157 shows consistent benefits across tissues as different as gastric mucosa, Achilles tendons, peripheral nerves, and cardiac muscle.
Human Evidence: What We Know from Published Studies
As of early 2026, three human studies on BPC-157 have been published. All three showed positive results. All three reported zero adverse events. While these are pilot studies with small sample sizes — and the peptide community is rightly eager for larger trials — they represent real human data that's consistent with the extensive preclinical evidence.
Intra-Articular BPC-157 for Multiple Types of Knee Pain
Study: Lee & Padgett, Alternative Therapies in Health and Medicine, 2021 | Patients: 16 contacted (of 17 enrolled) | Design: Retrospective, Institute for Hormonal Balance, Orlando, FL | Follow-up: 6-12 months
Results: 12 patients received BPC-157 alone via intra-articular injection — 11 of 12 (91.6%) had significant improvement in knee pain. 4 patients received BPC-157 + TB-500 combination — 3 of 4 (75%) improved. Overall: 14 of 16 patients (87.5%) had significant relief, with 7 of 12 BPC-157-only patients maintaining relief for over 6 months. Conditions included osteoarthritis, meniscus tears, tendinosis, and ligament injuries. Zero adverse events reported.
Significance: First published human study demonstrating BPC-157's effectiveness for musculoskeletal pain. Results held across multiple knee pathologies, suggesting the peptide's healing effects aren't condition-specific — they work at the tissue repair level regardless of what caused the damage.
BPC-157 for Treatment-Resistant Bladder Pain Syndrome
Study: Lee, Walker & Ayadi, Alternative Therapies in Health and Medicine, 2024 | Patients: 12 women (ages 39-76) | Design: Pilot study, IRB-approved | Dose: 10 mg BPC-157 injected intravesically (into bladder wall) during cystoscopy
Results: 10 of 12 patients (83%) reported 100% complete resolution of symptoms. The remaining 2 patients reported 80% symptom resolution. All 12 patients scored 5/5 on the Global Response Assessment. No dropouts. Zero adverse events. Critically, all 12 patients had previously failed treatment with pentosan polysulfate — the only FDA-approved medication for interstitial cystitis.
Significance: This is arguably the most impressive human data point for any research peptide. Patients with a notoriously difficult-to-treat condition, who had already failed the FDA-approved treatment, experienced near-complete symptom resolution from a single BPC-157 treatment. The fact that these were treatment-resistant patients makes the results even more meaningful.
Safety of Intravenous BPC-157 Infusion in Healthy Adults
Study: Lee & Burgess, Alternative Therapies in Health and Medicine, 2025 | Patients: 2 healthy adults (58-year-old male, 68-year-old female) | Design: Pilot safety/pharmacokinetic study
Protocol: Day 1: 10 mg BPC-157 IV infusion over 1 hour. Day 2: 20 mg BPC-157 IV infusion over 1 hour. Monitored via vital signs, ECG, comprehensive metabolic panel, and thyroid function.
Results: Zero adverse events. No clinically meaningful changes in any monitored parameter — cardiac, hepatic, renal, thyroid, or metabolic function all remained normal. Plasma BPC-157 concentrations returned to baseline within 24 hours. This study is significant because it tested doses far higher than typical subcutaneous protocols (20 mg IV vs. 250-500 mcg SC) and still found no safety concerns, further supporting BPC-157's remarkable tolerance profile.
Three pilot studies with ~30 total subjects isn't a Phase III trial — and nobody is claiming it is. But consider the pattern: every human study published shows positive results with zero adverse events, across different conditions, different routes of administration, different doses (from micrograms to 20 milligrams), and different patient populations. This is entirely consistent with the 100+ animal studies that came before. The question isn't whether BPC-157 works in humans — the early data and overwhelming anecdotal evidence say it does. The question is why funding for larger trials remains elusive, and the answer lies in the economics of unpatentable compounds, not in the science.
Research-Backed Benefits: The Complete Evidence Map
The preclinical evidence base for BPC-157 is extraordinarily broad. A 2025 systematic review in the American Journal of Sports Medicine identified 544 articles published between 1993-2024, with 36 meeting inclusion criteria for their musculoskeletal focus alone. Here's the full picture across all applications:
| Application | Evidence Strength | Key Findings |
|---|---|---|
| Gastrointestinal healing | Extensive (original application) | Accelerated healing of gastric, duodenal, and colonic ulcers caused by NSAIDs, alcohol, stress, and surgery. Protective against NSAID-induced GI damage. Reduced inflammation markers and promoted mucosal healing in IBD models comparable to standard treatments. Faster anastomosis recovery. Protective against acid reflux esophageal damage. Effective orally due to gastric acid stability. |
| Tendon & ligament repair | Extensive + human data | Accelerated Achilles tendon healing with improved biomechanical properties and organized collagen fibers. Faster MCL recovery. Enhanced tendon outgrowth, tendocyte growth, and fibroblast proliferation. 87.5% significant knee pain relief in human pilot study (6-12 month follow-up). 2025 case series: 90%+ symptom improvement in quadriceps reattachment. |
| Muscle healing | Extensive | Accelerated recovery from crush injuries, transected muscles, and muscle wasting. Optimized inflammatory response during healing. Proper tissue remodeling rather than scar formation. |
| Bone healing | Moderate (rabbit models) | Improved bone callus formation and faster radiographic healing in segmental bone defect models. Effects likely driven by angiogenic properties and growth factor modulation. |
| Nerve regeneration | Strong | Accelerated peripheral nerve regeneration after sciatic nerve crush. Counteracted axonal/neuronal necrosis, demyelination, and cyst formation after spinal cord injury. Functional rescue across all stages of secondary injury phase. |
| Neuroprotection | Strong | Reduced brain edema and improved outcomes after TBI. Protective against dopaminergic neurotoxicity (Parkinson's models). Antidepressant-like effects via serotonin modulation. Anti-anxiety effects via GABAergic interaction. |
| Cardiovascular | Strong | Blood pressure normalization (counters both hyper- and hypotension). Anti-arrhythmic properties against digitalis-induced disturbances. Reversed severe multi-organ and vessel failure in occlusion models. |
| Liver protection | Strong | Hepatoprotective against alcohol-induced and NSAID-induced liver injury. Protective effects on liver function across multiple toxicity models. |
| Bladder / urological | Human data available | 80-100% symptom resolution in treatment-resistant interstitial cystitis (human pilot, 12 patients). Anti-inflammatory and epithelial restoration properties. |
| NSAID damage protection | Extensive (signature finding) | One of BPC-157's most consistently demonstrated effects — protection against NSAID damage to gastric mucosa, intestinal lining, liver, brain, and other organ systems. Practical significance: anyone taking NSAIDs regularly. |
If there's one application where BPC-157's evidence is nearly undeniable, it's protection against NSAID-induced damage. NSAIDs (ibuprofen, naproxen, aspirin, etc.) are among the most commonly used drugs worldwide, and their gastrointestinal, hepatic, and renal side effects are well-documented. BPC-157 has shown protective effects against NSAID damage across virtually every organ system studied. For the millions of people who rely on NSAIDs for pain management — especially athletes and anyone with chronic inflammatory conditions — this may be BPC-157's most immediately practical application.
Dosage Protocols: How to Use BPC-157
Standard Dosing
| Parameter | Standard Protocol | Aggressive/Acute | Maintenance |
|---|---|---|---|
| Dose per administration | 250-500 mcg | 500-750 mcg | 250 mcg |
| Frequency | 1-2x daily | 2x daily | 1x daily or every other day |
| Duration | 4-8 weeks | 2-4 weeks, then taper | Ongoing or cycled (8 on / 4 off) |
| Primary route | Subcutaneous injection | SC near injury site + systemic | SC or oral |
| Best for | General healing, injury recovery | Acute injuries, post-surgical | GI protection, ongoing support |
Oral vs. Injectable: When to Use Each
Oral Administration
Best for: GI conditions (gut healing, IBS, IBD, GERD, NSAID protection, leaky gut). BPC-157 is uniquely stable in gastric acid — most peptides are destroyed by stomach acid, but BPC-157 maintains full biological activity orally. This makes it the only major research peptide with a legitimate oral route. Dose: 250-500 mcg taken on empty stomach. Form: Capsules or liquid (reconstituted and swallowed). Some users hold sublingual briefly before swallowing for partial absorption.
Injectable (Subcutaneous)
Best for: Tendon/ligament injuries, muscle healing, systemic effects, joint pain, neuroprotection, cardiovascular benefits. Injection ensures full bioavailability for non-GI targets. Local vs. systemic: Injecting near the injury site may provide higher local concentrations, but studies confirm systemic effects from distant injection sites — the peptide circulates effectively. Dose: 250-500 mcg SC, using insulin syringes (29-31 gauge). Site rotation: Abdomen, thigh, or near injury.
Many experienced users employ a dual-route strategy — oral BPC-157 for ongoing GI protection (especially if taking NSAIDs) combined with subcutaneous injection near the target tissue for specific injuries. This covers both local and systemic healing pathways simultaneously. The oral dose provides gastric protection directly at the source, while the injectable dose ensures maximum bioavailability for musculoskeletal or systemic targets.
Reconstitution Quick Guide
BPC-157 arrives as lyophilized (freeze-dried) powder. Reconstitution is straightforward:
| Vial Size | BAC Water | Concentration | 250 mcg = | 500 mcg = |
|---|---|---|---|---|
| 5 mg | 2 mL | 2,500 mcg/mL | 0.10 mL (10 units) | 0.20 mL (20 units) |
| 5 mg | 1 mL | 5,000 mcg/mL | 0.05 mL (5 units) | 0.10 mL (10 units) |
| 10 mg | 2 mL | 5,000 mcg/mL | 0.05 mL (5 units) | 0.10 mL (10 units) |
Steps: (1) Swab both vial tops with alcohol. (2) Draw bacteriostatic water into insulin syringe. (3) Inject slowly against the vial wall — never directly onto the powder. (4) Swirl gently until dissolved — never shake. (5) Store reconstituted solution at 2-8°C (refrigerator). (6) Use within 3-4 weeks.
What to Expect: Healing Timeline
Stacking: BPC-157 Combinations
| Stack | Rationale | Best For |
|---|---|---|
| BPC-157 + TB-500 (The "Wolverine Stack") | Complementary mechanisms: BPC-157 drives angiogenesis and growth factors; TB-500 promotes actin polymerization and cell migration. Together they cover both vascular and structural healing pathways. The human knee study tested this combo in 4 patients (75% improvement). | Tendon/ligament injuries, muscle healing, post-surgical recovery, athletic injury rehab |
| BPC-157 + GHK-Cu | BPC-157 handles deep tissue healing and angiogenesis; GHK-Cu excels at collagen remodeling, extracellular matrix regulation, and gene expression modulation (4,000+ genes). Complementary for connective tissue and anti-aging. | Skin healing, anti-aging, wound care, connective tissue repair, cosmetic recovery |
| BPC-157 + KPV | BPC-157 heals and protects the gut lining; KPV (alpha-MSH fragment) provides targeted anti-inflammatory action in the GI tract. Powerful combination for inflammatory gut conditions. | IBD, IBS, gut inflammation, leaky gut, food sensitivities, GI recovery |
| BPC-157 + Thymosin Alpha-1 | BPC-157 handles tissue healing; Tα1 boosts adaptive immune function. Useful when healing needs immune system support (chronic infections, post-illness recovery). | Healing during illness, post-infection recovery, immune-compromised healing |
How BPC-157 Compares to Alternatives
| Feature | BPC-157 | TB-500 | PRP | Cortisone |
|---|---|---|---|---|
| Mechanism | Multi-pathway healing coordinator (VEGF, NO, growth factors, FAK-paxillin) | Actin polymerization, cell migration, anti-inflammatory | Concentrated platelet growth factors | Anti-inflammatory (suppresses immune response) |
| Promotes actual healing? | Yes — tissue regeneration | Yes — tissue remodeling | Yes — growth factor delivery | No — suppresses inflammation only, may weaken tissue long-term |
| Oral option? | Yes — stable in gastric acid | No | No (injection only) | Yes (but systemic side effects) |
| GI healing? | Primary application | Limited data | Not applicable | Harmful to GI lining |
| Cost per treatment | Low ($30-80/month) | Low-moderate ($50-100/month) | High ($500-2,000 per session) | Low ($50-200 per injection) |
| Self-administrable? | Yes | Yes | No (clinic required) | No (clinic required) |
| Human trial data | 3 pilot studies (~30 patients) | No published human trials for TB-500 specifically | Extensive (hundreds of trials) | Extensive |
| Long-term tissue effects | Promotes stronger tissue | Promotes tissue remodeling | Supports natural healing | May degrade cartilage/tendon over time |
BPC-157 occupies a unique position in this landscape. It's the only compound here that works across virtually every tissue type, can be taken orally for GI applications, is self-administrable, and is affordable enough for multi-week courses. PRP has more human clinical data, but requires expensive clinic visits and can't be self-administered. Cortisone is widely available but doesn't promote actual healing — and can damage tissue with repeated use. TB-500 is a good complement but lacks BPC-157's versatility and research breadth. For most healing applications, BPC-157 is the best starting point, and other modalities can be layered on as needed.
Safety Profile
BPC-157's safety profile is one of its most compelling features — and it's supported by hard data, not just the absence of reported problems:
What the Data Shows
No lethal dose established — LD1 not achieved even at extreme concentrations. Negative limit test at 2 g/kg administered both IV and orally in mice (for reference, this is thousands of times above typical doses). No organ toxicity in subchronic studies. No mutagenic effects. No carcinogenic effects. Zero adverse events across all three published human studies, including doses up to 20 mg IV. Decades of safety data from the Sikiric laboratory.
Reported Side Effects
Based on community experience and limited clinical observations, side effects are rare and mild: occasional nausea (more common with oral use), minor injection site reactions, infrequent headaches, rare instances of mild dizziness. These are generally transient and resolve without intervention. The 2025 IV safety study specifically monitored cardiac, hepatic, renal, thyroid, and metabolic function — all remained entirely normal at doses far exceeding standard protocols.
Prudent Considerations
Active malignancy: BPC-157's angiogenic properties are theoretically concerning for anyone with active cancer — new blood vessel formation could support tumor growth. However, Sikiric's 2025 response paper directly addressed speculative toxicity claims, noting that negative predictions about angiogenesis dysregulation were "completely ruled out" by actual study evidence. Still, active cancer is a reasonable contraindication out of caution. Pregnancy/breastfeeding: insufficient data. Drug interactions: theoretical interactions with NO-modulating medications.
Legal Status & The FDA Situation
The regulatory landscape for BPC-157 in the United States has been turbulent — and it's worth understanding what actually happened rather than just accepting "the FDA banned it" at face value.
In 2023, the FDA placed BPC-157 on its Category 2 list — substances that cannot be used by compounding pharmacies under sections 503A and 503B due to "insufficient safety data." This effectively cut off the legitimate medical supply chain that many physicians and patients relied on. The FDA's rationale centers on the lack of completed large-scale human clinical trials, not on any evidence of harm.
Here's the frustrating reality: the FDA requires extensive (and expensive) human trial data to approve a substance, but no company will fund those trials for BPC-157 because its naturally-derived sequence can't be exclusively patented. Meanwhile, the FDA restricts access to the compound because those trials don't exist. This creates a circular barrier that has nothing to do with safety concerns and everything to do with pharmaceutical economics. The 100+ published studies, three human trials with zero adverse events, negative limit test results, and decades of international clinical use exist outside this regulatory loop — but they don't satisfy FDA's specific pathway requirements.
Current availability (2026): BPC-157 remains available as a research chemical designated for in vitro and laboratory use. Personal use exists in a regulatory gray area. International availability varies — some countries permit access through compounding pharmacies or direct prescription. The compound is not a controlled substance. Advocacy groups continue to push for reclassification from Category 2 to Category 1, which would allow compounding pharmacies to produce it again under physician oversight.
Drug testing: Standard workplace drug panels do not test for BPC-157. However, WADA has prohibited it for competitive athletes (added to prohibited list in 2022 under S0 "unapproved substances"), and most major US sports leagues have followed suit. Competitive athletes should verify their sport's current testing policies.
Frequently Asked Questions
Is BPC-157 natural or synthetic?
How quickly will I notice effects?
Should I inject near the injury or does location not matter?
Can I take BPC-157 orally for non-gut conditions?
Is BPC-157 safe to use while taking NSAIDs?
What's the deal with the cancelled Phase I trial?
How does the research being primarily from one laboratory affect credibility?
BPC-157 vs. PRP — which is better for joint pain?
What should I look for when sourcing BPC-157?
Key Takeaways
BPC-157 is the most extensively studied healing peptide available, backed by 30+ years of research, 100+ published papers, three human studies with zero adverse events, and overwhelming real-world experience from millions of users worldwide. It works by coordinating the body's own healing systems — promoting angiogenesis, modulating nitric oxide, upregulating growth factors, and enhancing cell migration — across every tissue type it's been tested on. Its unique gastric acid stability makes it the only major peptide with a viable oral route. Its safety profile is exceptional by any standard: no lethal dose established, no organ toxicity, and no serious adverse events in any published study including IV doses 40-80x above typical protocols.
The gap between BPC-157's evidence base and its regulatory status reflects pharmaceutical economics, not scientific uncertainty. A compound derived from human gastric juice, with no patent protection, will never attract the billion-dollar investment needed for traditional FDA approval — regardless of how promising the data is. That's a structural problem with how we fund drug development, not a problem with BPC-157.
For anyone dealing with injury recovery, gut health challenges, chronic pain, or tissue protection — BPC-157 deserves serious consideration. Start with a clear objective, source high-quality product, follow established dosing protocols, and give it adequate time to work. The research says it will.
This article is for educational and informational purposes only. It is not medical advice. BPC-157 is not FDA-approved for human use and is classified as a research compound in the United States. The FDA has placed BPC-157 on its Category 2 list, restricting compounding pharmacy access. The human studies cited are pilot studies with small sample sizes. While the preclinical evidence base is extensive and the safety profile appears favorable, large-scale randomized controlled trials in humans have not been completed. Consult a qualified healthcare provider before beginning any peptide protocol. Quality control in unregulated peptide markets poses sourcing risks.
References
Human Studies
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435.
Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID: 39325560.
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID: 40131143.
Systematic Reviews
Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Am J Sports Med. 2025. PMID: 40756949.
McGuire FM, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619.
Matek D, Matek I, Staresinic M, et al. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle. Pharmaceutics. 2025;17(1):119.
Key Preclinical Research
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135. PMID: 23829361.
Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2018;9:1408.
Sikiric P, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals. 2025;18(10):1450.
Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key. Pharmaceuticals. 2025;18(6):928.
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. PMID: 27900448.
Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID: 21030672.
Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983.
Tudor M, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept. 2010;160(1-3):26-32. PMID: 19931579.
Gjurasin M, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept. 2010;160(1-3):33-41. PMID: 19903499.
Sebecic B, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits. Bone. 1999;24(3):195-202. PMID: 10071910.
Vukojevic J, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487.